Ignite Creation Date:
2024-05-05 @ 9:37 PM
Last Modification Date:
2024-10-26 @ 10:06 AM
Study NCT ID:
NCT00920205
Status:
COMPLETED
Last Update Posted:
2011-10-14
First Post:
2009-06-12
Brief Title:
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
Sponsor:
Myrexis Inc
Organization:
Myrexis Inc
Study Overview
Official Title:
Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see how safe the study drug is and to determine the best dose to use in cancer patients in the future
The study drug is designed to reduce the activity of a protein known as heat shock protein 90 or Hsp90 Hsp90 is found in every cell in the human body and normally helps those cells and the body cope with stressful situations In certain cancers however Hsp90 helps the cancer cells survive and grow By reducing the activity of Hsp90 the study drug may slow the growth and reduce the survival of those cancer cells
The study drug is designed to reduce the activity of a protein known as heat shock protein 90 or Hsp90 Hsp90 is found in every cell in the human body and normally helps those cells and the body cope with stressful situations In certain cancers however Hsp90 helps the cancer cells survive and grow By reducing the activity of Hsp90 the study drug may slow the growth and reduce the survival of those cancer cells
Detailed Description:
This is a dose escalation study As subjects participating in the study tolerate a specific dose level the new subjects entering will be given a higher dose of the study drug
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None